Skip to main content

Advertisement

SpringerLink
Log in

CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Previous reports indicate that discordance between CYP2C19 genotype and enzyme function occurs in up to 37 % of cancer patients with a range of solid tumours. The aim of this study was to determine whether this acquired loss of function in hepatic CYP2C19 activity also occurs in patients with haematological malignancy.

Methods

CYP2C19 genotype was determined in 25 patients with multiple myeloma using PCR–RFLP analysis for the common allelic variants (*2, 681G>A, rs4244285; *3, 636G>A, rs49486893, and *17, −806C>T, rs12248560). The activity of the enzyme was evaluated using the CYP2C19 probe drug proguanil, and a metabolic ratio used to categorise subjects as extensive or poor metabolisers (PM).

Results

No genotypic PM (homozygous null) were detected in this patient cohort. However, CYP2C19 activity was severely compromised in some multiple myeloma patients, resulting in a PM status in 28 % of subjects. Hence, there was significant (p < 0.0001) discordance between the CYP2C19 activity predicted by genotype and the measured phenotype. Discordant CYP2C19 activity did not correlate with any of the pro-inflammatory markers studied.

Conclusions

Acquired loss of CYP2C19 activity occurs in a substantial proportion of patients with multiple myeloma. This indicates that the previously reported phenomenon is not limited to patients with solid tumours. Thus, measurement of CYP2C19 activity rather than CYP2C19 genotype may be more clinically relevant for the determination of whether loss of CYP2C19 function adversely influences the toxicity and efficacy of certain drugs used in medical oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K, Montemurro M, Roots I, Cascorbi I (2005) Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 5(6):365–373

    Article  CAS  PubMed  Google Scholar 

  2. Matsuzawa N, Nakamura K, Matsuda M, Ishida F, Ohmori S (2012) Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients. Biol Pharm Bull 35(3):317–320

    Article  CAS  PubMed  Google Scholar 

  3. Uttamsingh V, Lu C, Miwa G, Gan L-S (2005) Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 33(11):1723–1728

    Article  CAS  PubMed  Google Scholar 

  4. van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van‘t Veer LJ (2011) The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics 12(8):1137–1146

    Article  PubMed  Google Scholar 

  5. Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S (2013) The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Ann Oncol 24(6):1653–1659

    Article  CAS  PubMed  Google Scholar 

  6. Goldstein J, Blaisdell J (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 272:210–218

    Article  CAS  PubMed  Google Scholar 

  7. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913–958

    Article  CAS  PubMed  Google Scholar 

  8. Helsby NA, Lo WY, Sharples K, Riley G, Murray M, Spells K, Dzhelai M, Simpson A, Findlay M (2008) CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. Br J Cancer 99(8):1251–1255

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Williams ML, Bhargava P, Cherrouk I, Marshall JL, Flockhart DA, Wainer IW (2000) A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol 49(5):485–488

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Rivory LP, Slaviero KA, Clarke SJ (2002) Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87(3):277–280

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Baldwin R, Ohlsson S, Pedersen R, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L (2008) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65(5):767–774

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM (1990) The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 30(4):593

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Herrlin K, Massele AY, Rimoy G, Alm C, Rais M, Ericsson Ö, Bertilsson L, Gustafsson LL (2000) Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype. Clin Pharmacol Ther 68(2):189–198

    Article  CAS  PubMed  Google Scholar 

  14. Kato R, Takanaka A, Oshima T (1968) Drug metabolism in tumor-bearing rats. II. In vivo metabolisms and effects of drugs in tumor-bearing rats. Jpn J Pharmacol 18(2):245

    Article  CAS  PubMed  Google Scholar 

  15. Sugawara M, Okamoto K, Kadowaki T, Kusano K, Fukamizu A, Yoshimura T (2009) Inoculation of human tumor cells alters the basal expression but not the inducibility of cytochrome P450 enzymes in tumor-bearing mouse liver. Drug Metab Dispos 37(11):2244–2254

    Article  CAS  PubMed  Google Scholar 

  16. Kacevska M, Downes MR, Sharma R, Evans RM, Clarke SJ, Liddle C, Robertson GR (2011) Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. Clin Cancer Res 17(10):3170–3180

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Roh H-K, Dahl M-L, Tybring G, Yamada H, Cha Y-N, Bertilsson L (1996) CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenet Genomics 6(6):547–551

    Article  CAS  Google Scholar 

  18. Pascussi J, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem M (2003) The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta (BBA) Gen Subj 1619(3):243–253

    Article  CAS  Google Scholar 

  19. Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B (2000) In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 67(1):32–43

    Article  CAS  PubMed  Google Scholar 

  20. de Graan A-JM, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, de Vos AI, van Alphen RJ, van der Holt B, Verweij J (2011) Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol 29(24):3240–3246

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a research grant from the Leukaemia and Blood Foundation of NZ. We also wish to thank the patients for their involvement in this study.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

    K. E. Burns, M. A. Goldthorpe, F. Porteus, P. Browett & N. A. Helsby

Authors
  1. K. E. Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Goldthorpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Porteus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Browett
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. A. Helsby
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. A. Helsby.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burns, K.E., Goldthorpe, M.A., Porteus, F. et al. CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity. Cancer Chemother Pharmacol 73, 651–655 (2014). https://doi.org/10.1007/s00280-014-2409-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-014-2409-9

Keywords

Search

Navigation